tiprankstipranks
Trending News
More News >

Telix Pharmaceuticals Updates Director’s Interest in Securities

Story Highlights
  • Telix Pharmaceuticals focuses on oncology with molecularly targeted radiation products.
  • Director Dr. Behrenbruch acquires PSARs and SRs, aligning compensation with performance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Telix Pharmaceuticals Updates Director’s Interest in Securities

Don’t Miss TipRanks’ Half-Year Sale

Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.

Telix Pharmaceuticals has announced a change in the director’s interest, specifically for Dr. Christian Behrenbruch, who has acquired 166,483 Performance Share Appreciation Rights (PSARs) and 2,595 Deferred Share Rights (SRs) as part of his remuneration package. This change reflects the company’s commitment to aligning executive compensation with performance goals, potentially impacting the company’s operational focus and stakeholder interests by incentivizing leadership to achieve significant revenue milestones.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets the oncology market, aiming to improve cancer diagnosis and treatment through innovative radiopharmaceuticals.

Average Trading Volume: 1,600,992

Technical Sentiment Signal: Buy

Current Market Cap: A$8.66B

See more data about TLX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1